# US 2024/0059677 A1 · Substituted pyrimidine derivatives as nicotinic acetylcholinesterase receptor alpha 6 modulator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0059677 A1
- Document ID: US20240059677A1
- Status: Published application
- Kind: A1
- Application number: 18/025,315
- Filed: 2021-09-10
- Published: 2024-02-22
- Earliest claimed: 2020-09-11
- Assignees: Cerevance, Inc.; Takeda Pharmaceutical Company Limited
- Applicants: Cerevance, Inc.; Takeda Pharmaceutical Company Limited
- Inventors: Roland Werner Burli; Martin Teall; Nicola Brice
- Web page: https://patentgrep.com/patent/US20240059677A1

## CPC

- C07D 239/12: Nitrogen atoms not forming part of a nitro radical
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 239/14: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07B 2200/07: Optical isomers
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein in, R1, R2, R3, L and X are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy particularly for use in treating disorders associated with nicotinic acetylcholine receptor α6 (nAChRα6) activity.

## Claims

### Claim 1

A compound of formula (I):
or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
X is N or CR4;
L is a bond, —C(O)—, —C(O)—C(R5)2—, —C(R5)2—, or —C(R5)2C(R5)2—;
each R1 is independently selected from halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
m is 2, 3, 4 or 5;
R2 is selected from halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
R3 is selected from a C3-C6 cycloalkyl and 4- to 10-membered heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally substituted with one, two, three, four or five substituents independently selected from halo, cyano, hydroxy, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, C3-C6 halocycloalkoxy, —N(R6)2, and —SO2(R6);
R4 is selected from hydrogen, halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
each R5 is independently selected from hydrogen, CH3, CH2CH3, and CF3; and
each R6 is independently selected from hydrogen and C1-C3 alkyl, or two R6 together with the nitrogen to which they are attached form a 3- to 6-membered saturated heterocyclic group;
provided the compound is not:
4-methoxy-5-(2-methyl-4-(trifluoromethoxy)phenyl)-N-((1s,4s)-4-methylcyclohexyl)pyrimidin-2-amine;
4-methoxy-5-(2-methoxy-4-(trifluoromethoxy)phenyl)-N-((1s,4s)-4-methylcyclohexyl)pyrimidin-2-amine; or
N-cyclopropyl-5-(3,4-dimethoxyphenyl)-4-methyl-pyrimidin-2-amine.

### Claim 2 (depends on 1)

The compound as claimed in claim 1, wherein X is N.

### Claim 3 (depends on 1)

The compound as claimed in claim 1, wherein X is CR4.

### Claim 4 (depends on 3)

The compound as claimed in claim 3, wherein R4 is selected from hydrogen, halo, cyano, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, C1-C3 haloalkoxy, and cyclopropoxy.

### Claim 5 (depends on 1)

The compound as claimed in claim 1, wherein each R1 is independently selected from halo, cyano, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, an C1-C3 haloalkoxy.

### Claim 6 (depends on 1)

The compound as claimed in claim 1, wherein m is 2.

### Claim 7 (depends on 1)

The compound as claimed in any one of the claim 1, wherein R2 is selected from halo, cyano, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C1-C3 alkoxy, C1-C3 haloalkoxy, and cyclopropoxy.

### Claim 8 (depends on 1)

The compound as claimed in any one of the claim 1, wherein L is a bond, —C(O)—, —C(O)—CH2—, —C(O)—CH(CH3)—, —C(O)—CH(CF3)—, —CH2—, —CH(CH3)—, —CH(CF3)—, —CH2CH2—, —CH2—CH(CH3)—, —CH2—CH(CF3)—, —CH(CH3)—CH2—, or —CH(CF3)—CH2—.

### Claim 9 (depends on 1)

The compound as claimed in claim 1, wherein R3 is selected from a C3-C6 cycloalkyl group, a 4-, 5- or 6-membered saturated monocyclic heterocyclic group, a 7-, 8-, 9- or 10-membered saturated bicyclic heterocyclic group, and a 5- or 6-membered heteroaryl group, each of which is optionally substituted.

### Claim 10 (depends on 1)

The compound as claimed in any one of the claim 1, wherein the cycloalkyl or heterocyclic group of R3 is optionally substituted with one, two, three, four or five substituents independently selected from halo, cyano, hydroxy, C1-C3 alkyl, C1-C3 haloalkyl, C1-C3 alkoxy, C1-C3 haloalkoxy, —N(R6)2, and —SO2(R6), wherein each R6 is independently selected from hydrogen and C1-C3 alkyl.

### Claim 11 (depends on 1)

The compound as claimed in claim 1, wherein the compound is selected from:
4-methyl-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-5-phenylpyrimidin-2-amine;
N-(2-(1-methylpyrrolidin-2-yl)ethyl)-5-phenylpyrimidin-2-amine;
5-(4-fluorophenyl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)pyrimidin-2-amine;
5-(4-fluorophenyl)-N-((1-methylpiperidin-3-yl)methyl)pyrimidin-2-amine;
5-(4-fluorophenyl)-N-(1-methylpiperidin-3-yl)pyrimidin-2-amine;
5-(4-fluorophenyl)-N-(1-isopropylpiperidin-3-yl)pyrimidin-2-amine;
N1-(5-(4-fluorophenyl)pyrimidin-2-yl)-N3,N3-dimethylcyclohexane-1,3-diamine;
5-(4-fluorophenyl)-N-((1-methylpiperidin-2-yl)methyl)pyrimidin-2-amine;
5-(4-fluorophenyl)-N-(1-isopropylpiperidin-3-yl)-4-methyl-pyrimidin-2-amine;
5-(2,4-difluorophenyl)-N-((1-ethylpiperidin-2-yl)methyl)-4-methyl-pyrimidin-2-amine;
5-(2,4-difluorophenyl)-N-((1-(dimethylamino)cyclopentyl)methyl)-4-methyl-pyrimidin-2-amine;
N-(5-(2,4-difluorophenyl)-4-methyl-pyrimidin-2-yl)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine;
5-(2,4-difluorophenyl)-4-methyl-N-((1-methylpyrrolidin-3-yl)methyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-(2-(1-methylpyrrolidin-2-yl)ethyl)pyrimidin-2-amine;
6-(2,4-difluorophenyl)-5-methyl-N-((1-methylpyrrolidin-2-yl)methyl)-1,2,4-triazin-3-amine;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-(2-(1-methylpyrrolidin-2-yl)ethyl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-((1-methylpiperidin-2-yl)methyl)pyrimidin-2-amine;
6-(2-fluoro-4-methoxyphenyl)-5-methyl-N-((1-methylpyrrolidin-2-yl)methyl)-1,2,4-triazin-3-amine;
5-(2,4-difluorophenyl)-2-(((1-methylpyrrolidin-2-yl)methyl)amino)pyrimidine-4-carbonitrile;
6-(2,4-difluorophenyl)-5-methyl-N-((1-methylpiperidin-2-yl)methyl)-1,2,4-triazin-3-amine;
6-(2,4-difluorophenyl)-5-methyl-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-1,2,4-triazin-3-amine;
5-(2,4-difluorophenyl)-N-(1-isopropylpyrrolidin-3-yl)-4-methyl-pyrimidin-2-amine;
6-(2-fluoro-4-methoxyphenyl)-5-methyl-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-1,2,4-triazin-3-amine;
5-(2,4-difluorophenyl)-4-methyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-2-(((1-methylpiperidin-2-yl)methyl)amino)pyrimidine-4-carbonitrile;
6-(2-fluoro-4-methoxyphenyl)-5-methyl-N-((1-methylpiperidin-2-yl)methyl)-1,2,4-triazin-3-amine;
5-(2-fluoro-4-methoxyphenyl)-2-((2-(1-methylpyrrolidin-2-yl)ethyl)amino)pyrimidine-4-carbonitrile;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-(1-methylpyrrolidin-3-yl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-((1-methylpiperidin-3-yl)methyl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-2-(((1-methylpyrrolidin-3-yl)methyl)amino)pyrimidine-4-carbonitrile;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)pyrimidin-2-amine;
5-(2-fluoro-5-methoxyphenyl)-4-methyl-N-((1-methylpiperidin-2-yl)methyl)pyrimidin-2-amine;
5-(2-fluoro-5-methoxyphenyl)-4-methyl-N-((1-methylpiperidin-3-yl)methyl)pyrimidin-2-amine;
5-(2-chloro-4-methoxyphenyl)-4-methyl-N-((1-methylpiperidin-2-yl)methyl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-((4-methylmorpholin-2-yl)methyl)pyrimidin-2-amine;
4-cyclopropyl-5-(2-fluoro-4-methoxyphenyl)-N-((1-methylpyrrolidin-3-yl)methyl)pyrimidin-2-amine;
2-((3-(dimethylamino)cyclopentyl)amino)-5-(2-fluoro-4-methoxyphenyl)pyrimidine-4-carbonitrile;
N1-(6-(2,4-difluorophenyl)-5-methyl-1,2,4-triazin-3-yl)-N3,N3-dimethylcyclohexane-1,3-diamine;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-(1-methylpiperidin-4-yl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-N-(1-isopropylpiperidin-4-yl)-4-methyl-pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-(pyridin-3-ylmethyl)pyrimidin-2-amine;
N1-(5-(2-fluoro-4-methoxyphenyl)-4-(trifluoromethyl)pyrimidin-2-yl)-N3,N3-dimethylcyclopentane-1,3-diamine;
N1-(5-(2-fluoro-4-methoxyphenyl)-4-methyl-pyrimidin-2-yl)-N3,N3-dimethylcyclopentane-1,3-diamine;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-(tetrahydro-2H-pyran-3-yl)pyrimidin-2-amine;
5-(2-chloro-4-methoxyphenyl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-N-(1-isopropylpiperidin-3-yl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-N-((1-isopropylpiperidin-3-yl)methyl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-N-((1-isopropylpiperidin-2-yl)methyl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-4-methyl-N-((tetrahydro-2H-pyran-3-yl)methyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-(3-(methylsulfonyl)cyclopentyl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-N-(3-methoxycyclohexyl)-4-methyl-pyrimidin-2-amine;
N1-(5-(2,4-difluorophenyl)-4-methyl-pyrimidin-2-yl)-N3,N3-dimethylcyclohexane-1,3-diamine;
2-((3-(dimethylamino)cyclohexyl)amino)-5-(2-fluoro-4-methoxyphenyl)pyrimidine-4-carbonitrile;
5-(2,4-difluorophenyl)-2-((3-(dimethylamino)cyclopentyl)amino)pyrimidine-4-carbonitrile;
5-(2,4-difluorophenyl)-2-((3-(dimethylamino)cyclohexyl)amino)pyrimidine-4-carbonitrile;
5-(2,4-difluorophenyl)-4-methyl-N-(1-(2,2,2-trifluoroethyl)piperidin-3-yl)pyrimidin-2-amine;
5-(2-fluoro-5-methoxyphenyl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)pyrimidin-2-amine;
5-(2-chloro-4-methoxyphenyl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)pyrimidin-2-amine;
5-(2-chloro-4-methoxyphenyl)-4-methyl-N-((1-methyl-1H-imidazol-5-yl)methyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-(1-(1-methylpyrrolidin-3-yl)ethyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-2-((1-isopropylpiperidin-4-yl)amino)pyrimidine-4-carbonitrile;
5-(2,4-difluorophenyl)-2-((1-methylpiperidin-4-yl)amino)pyrimidine-4-carbonitrile;
5-(2,4-difluorophenyl)-N-(1-isopropylpiperidin-4-yl)-4-methyl-pyrimidin-2-amine;
N1-(5-(2,4-difluorophenyl)-4-methyl-pyrimidin-2-yl)-N3,N3-dimethylcyclobutane-1,3-diamine;
6-(2-fluoro-4-methoxyphenyl)-5-methyl-N-(1-methylpiperidin-3-yl)-1,2,4-triazin-3-amine;
5-(2-fluoro-4-methoxyphenyl)-4,6-dimethyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-(1-methylpiperidin-4-yl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-N-(1-isopropylpiperidin-3-yl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethoxy)phenyl)-4-methyl-N-(pyrrolidin-2-ylmethyl)pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-4-methoxy-6-methyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
6-(2-fluoro-4-methoxyphenyl)-N-(1-isopropylpiperidin-3-yl)-5-methyl-1,2,4-triazin-3-amine;
5-(2,4-difluorophenyl)-4-methyl-N-(1-methylpiperidin-3-yl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-N-(1-ethylpiperidin-3-yl)-4-methyl-pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)pyrimidin-2-amine;
N-((4,4-difluoro-1-methylpyrrolidin-2-yl)methyl)-5-(2,4-difluorophenyl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-methoxyphenyl)-2-((1-isopropylpiperidin-4-yl)amino)pyrimidine-4-carbonitrile;
5-(2,4-difluorophenyl)-4-methyl-N-(pyrrolidin-2-ylmethyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-N-((3,3-difluoropyrrolidin-2-yl)methyl)-4-methyl-pyrimidin-2-amine;
N-((3,3-difluoro-1-methylpyrrolidin-2-yl)methyl)-5-(2,4-difluorophenyl)-4-methyl-pyrimidin-2-amine;
5-(2,4-difluorophenyl)-N-((1-ethylpyrrolidin-2-yl)methyl)-4-methyl-pyrimidin-2-amine;
N-(5-(2,4-difluorophenyl)-4-methyl-pyrimidin-2-yl)hexahydro-1H-pyrrolizin-1-amine;
5-(2,4-difluorophenyl)-4-methyl-N-((1-(trideuteriomethyl)pyrrolidin-2-yl)methyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethoxy)phenyl)-N-(1-isopropylpiperidin-4-yl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethoxy)phenyl)-4-methyl-N-(1-methylpiperidin-4-yl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
5-(4-fluoro-2-(trifluoromethyl)phenyl)-4-methyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethoxy)phenyl)-4-methyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-((1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl)methyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-N-((3-fluoro-1-methylpyrrolidin-2-yl)methyl)-4-methyl-pyrimidin-2-amine;
N-(5-(2-fluoro-4-(trifluoromethoxy)phenyl)-4-methyl-pyrimidin-2-yl)hexahydro-1H-pyrrolizin-1-amine;
N-((1-ethylpyrrolidin-2-yl)methyl)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((1-methylpyrrolidin-3-yl)methyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-N-(1-isopropylpyrrolidin-3-yl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((1-methyl-4-piperidinyl)methyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(pyrrolidin-2-ylmethyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(2-piperidinylmethyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(2-(1-methylpyrrolidin-2-yl)ethyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((1-methyl-3-piperidinyl)methyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((4-methylmorpholin-2-yl)methyl)pyrimidin-2-amine;
N1-(5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)-N2,N2-dimethyl-cyclohexane-1,2-diamine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(pyrrolidin-3-yl)pyrimidin-2-amine;
N3-(5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)cyclopentane-1,3-diamine;
N-(4-fluoropyrrolidin-3-yl)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((3-piperidinyl)methyl)pyrimidin-2-amine;
4-((5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)amino)pyrrolidin-3-ol;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(3-piperidinyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((1-(trideuteriomethyl)pyrrolidin-2-yl)methyl)pyrimidin-2-amine;
N-(5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)quinuclidin-3-amine;
N-(5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-3-amine;
N-(5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)-2-azaspiro[3.3]heptan-6-amine;
N-(5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)-6-azaspiro[2.5]octan-1-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-N-(3-fluoropiperidin-4-yl)-4-methyl-pyrimidin-2-amine;
N1-(5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)cyclohexane-1,3-diamine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(piperidin-3-ylmethyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(piperidin-3-yl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(1-(pyrrolidin-2-yl)ethyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(1-(1-methylpyrrolidin-2-yl)ethyl)pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-N-((3-fluoropyrrolidin-2-yl)methyl)-4-methyl-pyrimidin-2-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((2-methyl-pyrrolidin-2-yl)methyl)pyrimidin-2-amine;
N-((1,2-dimethylpyrrolidin-2-yl)methyl)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-amine;
N-((1,5-dimethylpyrrolidin-2-yl)methyl)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-amine; and
N-(5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)-1-methylpyrrolidine-2-carboxamide;
or an enantiomer of any of the foregoing;
or a pharmaceutically acceptable salt, solvate or prodrug of any of the foregoing.

### Claim 12 (depends on 1)

The compound as claimed in claim 1, wherein the compound is selected from:
(R)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
(R)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(pyrrolidin-2-ylmethyl)pyrimidin-2-amine;
(S)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-(pyrrolidin-2-ylmethyl)pyrimidin-2-amine;
N-(5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-yl)-2-azaspiro[3.3]heptan-6-amine;
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((1*S)-1-((2S)-pyrrolidin-2-yl)ethyl)pyrimidin-2-amine; and
N-(((2*S,5*R)-1,5-dimethylpyrrolidin-2-yl)methyl)-5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-pyrimidin-2-amine;
or a pharmaceutically acceptable salt, solvate or prodrug of any of the foregoing.

### Claim 13 (depends on 1)

The compound as claimed in claim 1, wherein the compound is selected from:
(S)-5-(2,4-difluorophenyl)-4-methyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
(R)-5-(2,4-difluorophenyl)-4-methyl-N-((1-methylpyrrolidin-2-yl)methyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-N-(1-isopropylpiperidin-4-yl)-4-methyl-pyrimidin-2-amine;
(R)-5-(2,4-difluorophenyl)-N-(1-ethylpiperidin-3-yl)-4-methyl-pyrimidin-2-amine;
(S)-5-(2,4-difluorophenyl)-N-(1-ethylpiperidin-3-yl)-4-methyl-pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-(pyrrolidin-2-ylmethyl)pyrimidin-2-amine;
5-(2,4-difluorophenyl)-4-methyl-N-((1-(trideuteriomethyl)pyrrolidin-2-yl)methyl)pyrimidin-2-amine;
(S)-5-(2,4-difluorophenyl)-4-methyl-N-((1-(trideuteriomethyl)pyrrolidin-2-yl)methyl)pyrimidin-2-amine;
(R)-5-(2,4-difluorophenyl)-4-methyl-N-((1-(trideuteriomethyl)pyrrolidin-2-yl)methyl)pyrimidin-2-amine;
(R)-5-(2,4-difluorophenyl)-4-methyl-N-(pyrrolidin-2-ylmethyl)pyrimidin-2-amine;
(S)-5-(2,4-difluorophenyl)-4-methyl-N-(pyrrolidin-2-ylmethyl)pyrimidin-2-amine; and
5-(2-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-N-((3S)-3-piperidinyl)pyrimidin-2-amine;
or a pharmaceutically acceptable salt, solvate or prodrug of any of the foregoing.

### Claim 14 (depends on 1)

A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein the process comprises:
(a) reacting a compound of formula (II) or a salt thereof, with a compound of formula (III) or a salt thereof, to provide a compound of formula (IV) or a salt thereof:
wherein m, R1, R2 and X are as defined in claim 1; R7 is independently selected from hydroxy, C1-C5 alkyl, and C1-C5 alkoxy, or two R7 together with the boron to which they are attached form an optionally substituted 3- to 12-membered heterocyclic group; and LG1 and LG2 are leaving groups, or a sulfonate group;
(b) reacting a compound of formula (IV) or a salt thereof, with a compound of formula (V) or a salt thereof, to provide a compound of formula (I) or a salt thereof:
wherein R3 and L are as defined in claim 1;
and optionally thereafter carrying out one or more of the following procedures:
converting a compound of formula (I) into another compound of formula (I);
removing any protecting groups;
forming a pharmaceutically acceptable salt, solvate or prodrug.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, in association with a pharmaceutically acceptable adjuvant, diluent or carrier, and optionally one or more other therapeutic agents.

### Claim 16

(canceled)

### Claim 17

A method of treating or preventing a disease, disorder or condition, wherein the method comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
X is N or CR4;
L is a bond, —C(O)—, —C(O)—C(R5)2—, —C(R5)2—, or —C(R5)2C(R5)2—;
each R1 is independently selected from halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
m is 0, 1, 2, 3, 4 or 5;
R2 is selected from hydrogen, halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
R3 is selected from a C3-C6 cycloalkyl and 4- to 10-membered heterocyclic group, wherein the cycloalkyl or heterocyclic group is optionally substituted with one, two, three, four or five substituents independently selected from halo, cyano, hydroxy, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, C3-C6 halocycloalkoxy, —N(R6)2, and —SO2(R6);
R4 is selected from hydrogen, halo, cyano, C1-C5 alkyl, C1-C5 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C3-C6 cycloalkoxy, and C3-C6 halocycloalkoxy;
each R5 is independently selected from hydrogen, CH3, CH2CH3, and CF3; and
each R6 is independently selected from hydrogen and C1-C3 alkyl, or two R6 together with the nitrogen to which they are attached form a 3- to 6-membered saturated heterocyclic group;
wherein the disease, disorder or condition is associated with nicotinic acetylcholine receptor α6 (nAChRα6) activity: or wherein the disease, disorder or condition has dysregulation of dopamine, noradrenaline or serotonin as a key pathological mechanism; or wherein the disease, disorder or condition is selected from a movement disorder, dystonia, dyskinesia, Parkinson's disease, Huntington's disease, a psychiatric disorder, an addiction disorder, and a non-motor symptom of Parkinson's disease.

### Claim at position 18

18-21. (canceled)

### Claim 22 (depends on 17)

The method of claim 17, wherein the movement disorder is tremor; or wherein the dyskinesia is L-DOPA induced dyskinesia in Parkinson's disease; or wherein the psychiatric disorder is selected from schizophrenia, psychotic disorder, psychosis, schizoaffective disorder, bipolar disorder, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and Tourettes syndrome; or wherein the addiction disorder is selected from substance or drug dependence, alcohol dependence, nicotine dependence, binge eating, and gambling disorder; or wherein the non-motor symptom of Parkinson's disease is selected from apathy, anhedonia, and depression.

### Claim 23 (depends on 22)

The method of claim 22, wherein the tremor is selected from a resting tremor in Parkinson's disease and essential tremor including essential tremor in isolation, essential tremor in Parkinson's disease, essential tremor in Alzheimer's disease, and essential tremor in other neurodegenerative diseases; or wherein the bipolar disorder is selected from bipolar I, bipolar IL, bipolar mania, and bipolar depression; or wherein the autism spectrum disorder (ASD) is Fragile X syndrome.
